{"entity":{"id":"edgewood-oncology","kind":"company","name":"Edgewood Oncology","aka":[],"tldr":"Edgewood Oncology is developing BTX-A51, a pill that blocks three enzymes cancer cells rely on, for acute myeloid leukaemia, a genetically defined form of breast cancer and liposarcoma.","summary":"Edgewood Oncology is a clinical-stage company founded to develop BTX-A51, a first-in-class oral small molecule that inhibits casein kinase 1 alpha (CK1α) together with the transcriptional kinases CDK7 and CDK9. Edgewood acquired the rights to BTX-A51 from Yissum, the technology transfer company of the Hebrew University of Jerusalem. It emerged from stealth on 25 March 2024 with a USD 20 million Series A backed by Alta Partners, to pursue acute myeloid leukaemia and a precision medicine approach in breast cancer, including GATA3-mutant breast cancer. In April 2025 it announced the first patient dosed in a phase 1 investigator-sponsored study of BTX-A51 in liposarcoma. David N. Cook is chief executive and Zung Thai is chief medical officer.","asOf":"2026-10-29","links":[{"label":"Official website","url":"https://www.edgewoodoncology.com/"},{"label":"Launch and Series A release, March 2024","url":"https://www.edgewoodoncology.com/news/edgewood-oncology-emerges-from-stealth-with-20-million-in-series-a-financing-to-advance-btx-a51-in-patients-with-hematologic-malignancies-and-genetically-defined-solid-tumorsnbsp"}],"tags":[],"related":[],"cancers":["aml","breast-cancer","liposarcoma"],"sections":["targeted-therapy"],"technologies":["kinase-inhibitors"],"targets":["csnk1a1","cdk9"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not stated; the company says only that it was founded to deliver on BTX-A51. Headquarters is taken from the Brookline dateline of the launch release. CDK7 has no target record and is not linked. Trial registry numbers were not given on the pages read."],"hq":"Brookline, MA","country":"US","companyType":"biotech","website":"https://www.edgewoodoncology.com/","stage":"startup","investors":[],"funding":[{"round":"Series A","year":2024,"amountUsd":20000000,"source":"https://www.edgewoodoncology.com/news/edgewood-oncology-emerges-from-stealth-with-20-million-in-series-a-financing-to-advance-btx-a51-in-patients-with-hematologic-malignancies-and-genetically-defined-solid-tumorsnbsp","note":"Backed by Alta Partners"}]},"route":"/companies/edgewood-oncology/","neighbours":{"cancer":[{"id":"aml","kind":"cancer","name":"Acute myeloid leukaemia","route":"/cancers/aml/"},{"id":"breast-cancer","kind":"cancer","name":"Breast cancer (all types)","route":"/cancers/breast-cancer/"},{"id":"liposarcoma","kind":"cancer","name":"Liposarcoma","route":"/cancers/liposarcoma/"}],"section":[{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"cdk9","kind":"target","name":"CDK9","route":"/targets/cdk9/"},{"id":"csnk1a1","kind":"target","name":"CSNK1A1","route":"/targets/csnk1a1/"}]}}